(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -38.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Novavax's revenue in 2025 is $1,064,651,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $62,308,614,643, with the lowest NVAX revenue forecast at $39,761,879,087, and the highest NVAX revenue forecast at $96,283,904,517. On average, 9 Wall Street analysts forecast NVAX's revenue for 2027 to be $41,198,370,202, with the lowest NVAX revenue forecast at $22,454,111,129, and the highest NVAX revenue forecast at $78,428,514,947.
In 2028, NVAX is forecast to generate $53,337,045,129 in revenue, with the lowest revenue forecast at $43,214,982,730 and the highest revenue forecast at $75,927,655,414.